If tafasitamab/lenalidomide plus R-CHOP (frontMIND) is approved/utilized for frontline treatment, how would you approach second-line therapy in transplant-ineligible patients with relapsed/refractory DLBCL?

I do not think my approach to transplant-ineligible R/R DLBCL will significantly change, other than not using Tafasitamab-Len. I will still consider CAR-T cell therapy as a treatment option, as Tafa does not seem to affect the efficacy of CD19 CAR-T (Sakemura et al., PMID 37879074, and also Bastos-O...